Published in HPB (Oxford) on May 18, 2011
Patient readmission and mortality after surgery for hepato-pancreato-biliary malignancies. J Am Coll Surg (2012) 1.55
Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg (2015) 1.46
Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg (2013) 1.14
Treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma: a national perspective. J Am Coll Surg (2013) 1.02
Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. Ann Surg Oncol (2014) 1.00
A risk model to predict 90-day mortality among patients undergoing hepatic resection. J Am Coll Surg (2013) 0.95
Management of biliary cystic tumors: a multi-institutional analysis of a rare liver tumor. Ann Surg (2015) 0.94
Postoperative mortality is an inadequate quality indicator for lung cancer resection. Ann Thorac Surg (2014) 0.92
Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86
Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series. HPB (Oxford) (2015) 0.86
Safe hepatectomy selection criteria for hepatocellular carcinoma patients: a validation of 336 consecutive hepatectomies. The BILCHE score. World J Surg (2015) 0.86
Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg (2015) 0.86
Evaluation of a laparoscopic liver resection in the setting of cirrhosis. HPB (Oxford) (2013) 0.84
Hepatectomy for hepatocellular carcinoma larger than 10 cm: preoperative risk stratification to prevent futile surgery. HPB (Oxford) (2015) 0.84
Incidence and treatment of local site recurrences following RFA of colorectal liver metastases. World J Surg (2013) 0.83
Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases. Mod Pathol (2015) 0.82
Synchronous primary colorectal and liver metastasis: impact of operative approach on clinical outcomes and hospital charges. HPB (Oxford) (2014) 0.82
Defining incidence and risk factors of venous thromboemolism after hepatectomy. J Gastrointest Surg (2013) 0.82
Liver resection and ablation for metastatic melanoma: A single center experience. J Surg Oncol (2015) 0.80
Improving the quality of liver resection: a systematic review and critical analysis of the available prognostic models. HPB (Oxford) (2014) 0.78
Prognostic value of the lymph node ratio after resection of periampullary carcinomas. HPB (Oxford) (2012) 0.76
Understanding drivers of hospital charge variation for episodes of care among patients undergoing hepatopancreatobiliary surgery. HPB (Oxford) (2015) 0.75
Major liver resection, systemic fibrinolytic activity, and the impact of tranexamic acid. HPB (Oxford) (2016) 0.75
Acute kidney injury following hepatectomy for hepatocellular carcinoma: incidence, risk factors and prognostic value. HPB (Oxford) (2016) 0.75
Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models. J Am Coll Surg (2016) 0.75
Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB (Oxford) (2016) 0.75
Nutritional risk screening 2002 and ASA score predict mortality after elective liver resection for malignancy. Arch Med Sci (2017) 0.75
Mortality-related risk factors and long-term survival after 4460 liver resections in Sweden-a population-based study. Langenbecks Arch Surg (2016) 0.75
Ninety-day readmissions after inpatient cholecystectomy: A 5-year analysis. World J Gastroenterol (2017) 0.75
Hepato-pancreatectomy: how morbid? Results from the national surgical quality improvement project. HPB (Oxford) (2015) 0.75
Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer. World J Surg (2017) 0.75
Comorbidity measures for use with administrative data. Med Care (1998) 46.67
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care (2002) 21.63
Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg (1999) 14.31
Linking physicians' pay to the quality of care--a major experiment in the United kingdom. N Engl J Med (2004) 13.05
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Validity of information on comorbidity derived rom ICD-9-CCM administrative data. Med Care (2002) 5.92
Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg (2000) 5.79
Comparison of the Elixhauser and Charlson/Deyo methods of comorbidity measurement in administrative data. Med Care (2004) 5.12
Publication bias and clinical trials. Control Clin Trials (1987) 4.34
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Publication bias: the problem that won't go away. Ann N Y Acad Sci (1993) 3.23
Hepatic resection for hepatocellular carcinoma. An audit of 343 patients. Ann Surg (1995) 3.04
Major hepatic resection. A 25-year experience. Ann Surg (1983) 2.55
In search of the perfect comorbidity measure for use with administrative claims data: does it exist? Med Care (2006) 2.53
No-mortality liver resection for hepatocellular carcinoma in cirrhotic and noncirrhotic patients: is there a way? A prospective analysis of our approach. Arch Surg (1999) 2.47
Three hundred and one consecutive extended right hepatectomies: evaluation of outcome based on systematic liver volumetry. Ann Surg (2009) 2.44
Portal vein embolization: rationale, technique and future prospects. Br J Surg (2001) 2.41
Hospital mortality of major hepatectomy for hepatocellular carcinoma associated with cirrhosis. Arch Surg (1995) 2.37
Risk adjustment performance of Charlson and Elixhauser comorbidities in ICD-9 and ICD-10 administrative databases. BMC Health Serv Res (2008) 2.12
Liver resection for hepatocellular carcinoma. Results of 229 consecutive patients during 11 years. Ann Surg (1993) 2.06
Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol (2007) 2.06
Measuring complications of cancer treatment using the SEER-Medicare data. Med Care (2002) 2.05
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
National trends in the use and outcomes of hepatic resection. J Am Coll Surg (2004) 1.92
Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg (2009) 1.85
Hepatic resection in the United States: indications, outcomes, and hospital procedural volumes from a nationally representative database. Arch Surg (2003) 1.74
Operative mortality after hepatic resection: are literature-based rates broadly applicable? J Gastrointest Surg (2008) 1.69
Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J Gastrointest Surg (2009) 1.41
Total and segmental liver volume variations: implications for liver surgery. Surgery (2004) 1.41
National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. J Gastrointest Surg (2010) 1.36
Hepatic resection in the elderly. Ann Surg (1990) 1.07
Study of completeness of the surveillance, epidemiology and end results (SEER) program case ascertainment by hospital size and casefinding source. Health Rep (1993) 1.06
Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) (2010) 1.04
A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985-2000. Surgery (2002) 1.01
Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy. World J Surg (2007) 1.00
Therapeutic efficacy of combined intraoperative ablation and resection for colorectal liver metastases: an international, multi-institutional analysis. J Gastrointest Surg (2010) 0.92
In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score. Cancer (2010) 0.90
Safety of liver resection in the elderly: how important is age? Ann Surg Oncol (2010) 0.88
Liver resection for hepatocellular carcinoma: results from 150 consecutive patients. Cancer Chemother Pharmacol (1989) 0.87
Single and multiple resections of multiple hepatic metastases of colorectal origin. Surgery (2004) 0.85
Redefining mortality after pancreatic cancer resection. J Gastrointest Surg (2010) 0.85
Abstracts of the Fifth Annual Academic Surgical Congress of the Association for Academic Surgery and Society of University Surgeons. San Antonio, Texas, USA. February 3-5, 2010. J Surg Res (2010) 0.80
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg (2009) 16.82
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell (2007) 13.04
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol (2006) 5.78
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Expression of Yes-associated protein in common solid tumors. Hum Pathol (2008) 4.61
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell (2010) 4.47
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev (2012) 4.19
Adiponectin and AdipoR1 regulate PGC-1alpha and mitochondria by Ca(2+) and AMPK/SIRT1. Nature (2010) 4.12
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res (2012) 3.68
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52
Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann Surg (2012) 2.48
SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res (2009) 2.44
Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol (2008) 2.43
Expanding criteria for resectability of colorectal liver metastases. Oncologist (2008) 2.39
Evolution of fluorescein as a platform for finely tunable fluorescence probes. J Am Chem Soc (2005) 2.35
Surgical treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Ann Surg Oncol (2009) 2.35
Patient readmission and mortality after colorectal surgery for colon cancer: impact of length of stay relative to other clinical factors. J Am Coll Surg (2012) 2.29
In vivo costimulatory role of B7-DC in tuning T helper cell 1 and cytotoxic T lymphocyte responses. J Exp Med (2005) 2.28
Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol (2007) 2.26
NFAT functions as a working memory of Ca2+ signals in decoding Ca2+ oscillation. EMBO J (2003) 2.24
Intrahepatic cholangiocarcinoma: management options and emerging therapies. J Am Coll Surg (2013) 2.22
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res (2012) 2.10
Solitary colorectal liver metastasis: resection determines outcome. Arch Surg (2006) 2.06
Limitations of claims and registry data in surgical oncology research. Ann Surg Oncol (2007) 2.06
Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol (2005) 2.03
Is extended hepatectomy for hepatobiliary malignancy justified? Ann Surg (2004) 2.01
Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. AJR Am J Roentgenol (2015) 2.00
Pancreatic resection of isolated metastases from nonpancreatic primary cancers. Ann Surg Oncol (2008) 1.97
Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet (2002) 1.96
Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer (2013) 1.94
The role of surgery in the management of isolated metastases to the pancreas. Lancet Oncol (2009) 1.94
Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol (2007) 1.94